Product
ABD-3001
Aliases
DIMATE
1 clinical trial
3 indications
Indication
Acute Myeloid LeukemiaIndication
AdultIndication
Myelodysplastic SyndromesClinical trial
First-In-Human, Open Label, Dose Escalation Study to Evaluate Safety, PK and PD of ABD-3001 as Monotherapy in Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes Patients, Ineligible for Intensive or New Generation Targeted Therapy.Status: Active (not recruiting), Estimated PCD: 2024-10-01